These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 30712412)

  • 21. Experimental and Clinical Treatment of Chagas Disease: A Review.
    Sales Junior PA; Molina I; Fonseca Murta SM; Sánchez-Montalvá A; Salvador F; Corrêa-Oliveira R; Carneiro CM
    Am J Trop Med Hyg; 2017 Nov; 97(5):1289-1303. PubMed ID: 29016289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characteristics of Patients for Whom Benznidazole Was Released Through the CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease - United States, 2011-2018.
    Herwaldt BL; Dougherty CP; Allen CK; Jolly JP; Brown MN; Yu P; Yu Y
    MMWR Morb Mortal Wkly Rep; 2018 Jul; 67(29):803-805. PubMed ID: 30048425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recognizing and meeting the challenge of Chagas disease in the USA.
    Bowling J; Walter EA
    Expert Rev Anti Infect Ther; 2009 Dec; 7(10):1223-34. PubMed ID: 19968514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole.
    Ferraz LRM; Alves AÉG; Nascimento DDSDS; Amariz IAE; Ferreira AS; Costa SPM; Rolim LA; Lima ÁAN; Rolim Neto PJ
    Acta Trop; 2018 Sep; 185():127-132. PubMed ID: 29452113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benznidazole shortage makes chagas disease a neglected tropical disease in developed countries: data from Spain.
    Navarro M; Norman FF; Pérez-Molina JA; López-Vélez R
    Am J Trop Med Hyg; 2012 Sep; 87(3):489-90. PubMed ID: 22826485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An update on benznidazole for the treatment of patients with Chagas disease.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2018 Jan; 54(1):15-23. PubMed ID: 29569658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New Approaches for the Treatment of Chagas Disease.
    Pandey RP; Nascimento MS; Moore CE; Raj VS; Kalil J; Cunha-Neto E
    Curr Drug Targets; 2021; 22(7):835-841. PubMed ID: 33238855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas' disease, in a field area with interrupted transmission. I. Preliminary evaluation].
    Coura JR; de Abreu LL; Willcox HP; Petana W
    Rev Soc Bras Med Trop; 1997; 30(2):139-44. PubMed ID: 9148337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Nifurtimox, a bright future for treatment of Chagas disease].
    Wolf A; Boulliat C; Coillot C; Rouault M; Gaillard K; Beranger C; Oliver M
    Med Trop (Mars); 2011 Apr; 71(2):131-3. PubMed ID: 21695868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
    Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S
    PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [What is not searched, it is difficult to find: Chagas' disease].
    Briceno L; Mosca W
    G Ital Cardiol (Rome); 2016 May; 17(5):343-7. PubMed ID: 27310907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment.
    Pérez-Molina JA; Sojo-Dorado J; Norman F; Monge-Maillo B; Díaz-Menéndez M; Albajar-Viñas P; López-Vélez R
    Acta Trop; 2013 Aug; 127(2):101-4. PubMed ID: 23583863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis).
    Castro JA; de Mecca MM; Bartel LC
    Hum Exp Toxicol; 2006 Aug; 25(8):471-9. PubMed ID: 16937919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of nucleic acid amplification assays in monitoring treatment response in chagas disease: Usefulness in clinical trials.
    Sulleiro E; Muñoz-Calderon A; Schijman AG
    Acta Trop; 2019 Nov; 199():105120. PubMed ID: 31376368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Access to Chagas disease treatment in the United States after the regulatory approval of benznidazole.
    Yoshioka K; Manne-Goehler J; Maguire JH; Reich MR
    PLoS Negl Trop Dis; 2020 Jun; 14(6):e0008398. PubMed ID: 32569280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent clinical trials for the etiological treatment of chronic chagas disease: advances, challenges and perspectives.
    Urbina JA
    J Eukaryot Microbiol; 2015; 62(1):149-56. PubMed ID: 25284065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease.
    Filardi LS; Brener Z
    Trans R Soc Trop Med Hyg; 1987; 81(5):755-9. PubMed ID: 3130683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chagas disease and transfusion medicine: a perspective from non-endemic countries.
    Angheben A; Boix L; Buonfrate D; Gobbi F; Bisoffi Z; Pupella S; Gandini G; Aprili G
    Blood Transfus; 2015 Oct; 13(4):540-50. PubMed ID: 26513769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on nifurtimox for treatment of Chagas disease.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2021 Apr; 57(4):251-263. PubMed ID: 33851689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolerance and safety of nifurtimox in patients with chronic chagas disease.
    Jackson Y; Alirol E; Getaz L; Wolff H; Combescure C; Chappuis F
    Clin Infect Dis; 2010 Nov; 51(10):e69-75. PubMed ID: 20932171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.